Apellis Pharmaceuticals, Inc. SEC Filings

Apellis Pharmaceuticals director Dunlop A. Sinclair reported multiple dispositions of Apellis common stock on 09/30/2025. The filing shows a sale of 31,092 shares at a weighted average price of $22.58 (individual sale prices ranged from $22.23 to $22.74). The filer states these sales were executed under a Rule 10b5-1 trading plan adopted by Epidarex Capital I LP on June 20, 2025. The report lists an additional 3,837-share distribution at no consideration and includes a separate disposition line showing 158,393 shares disposed, without price detail in the table. Sinclair is identified as a director and as having indirect ownership through Epidarex, which holds voting and dispositive power over the shares.

Dunlop A. Sinclair, a director of Apellis Pharmaceuticals (APLS), reported multiple dispositions of Apellis common stock on 09/19/2025. Sales include 31,092 shares sold under a Rule 10b5-1 plan at a weighted-average price of $22.95 (execution prices ranged $22.73–$23.27). A separate distribution of 3,837 shares was recorded as a stock distribution for no consideration. The reported holdings after the first two transactions were 68,908 and 65,071 shares, respectively, held indirectly through Epidarex Capital I LP, of which Sinclair is a general partner and may be deemed to have voting and dispositive power. The Form 4 was signed by an attorney-in-fact on behalf of Sinclair.

Apellis Pharmaceuticals (APLS) filing a Form 144 shows a proposed sale of 93,276 shares of common stock for an aggregate market value of $2,140,917.00, to be executed through Stifel Nicolaus & Company on Nasdaq on 09/19/2025. The shares were acquired in three tranches: 62,441 shares on 08/21/2013, 31,478 shares on 12/24/2015, and 6,081 shares on 08/07/2017; all were paid in cash to the issuer. The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.

David O. Watson, General Counsel of Apellis Pharmaceuticals (APLS), reported a sale of 5,000 shares of Apellis common stock on 09/16/2025 at a price of $24.34 per share under a 10b5-1 trading plan dated March 3, 2025. After the reported transaction, Mr. Watson beneficially owns 118,730 shares directly. The filing also discloses 10,000 shares held in a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, over which he disclaims beneficial ownership except to the extent of any pecuniary interest. The Form 4 was signed on 09/18/2025.

Apellis Pharmaceuticals insider James G. Chopas, the company's VP and Chief Accounting Officer, reported a small sale of 189 shares of Apellis common stock on 09/15/2025 at a price of $24.192 per share. The filing states the shares were sold to cover tax withholding related to Restricted Stock Units that vested on 09/12/2025. After the transaction, Mr. Chopas beneficially owned 53,468 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/16/2025.

Apellis Pharmaceuticals (APLS) Form 144 notice summarizing proposed and recent insider sales. The filing reports a proposed sale of 5,000 common shares through Fidelity Brokerage Services with an aggregate market value of $121,700 and an approximate sale date of 09/16/2025. It shows two prior restricted stock vesting events: 706 shares on 01/21/2024 and 4,294 shares on 01/21/2025, both as compensation. The filing lists three common-share sales by David O. Watson in the past three months totaling $330,600 in gross proceeds. The company has 126,289,910 shares outstanding as stated.

Apellis Pharmaceuticals, Inc. (APLS) Form 144 notice reports a proposed sale of 189 shares of common stock held at Fidelity Brokerage Services with an aggregate market value of $4,572.29. The shares, part of restricted stock that vested on 09/12/2025, were acquired from the issuer as compensation and the filer plans an approximate sale date of 09/15/2025 on NASDAQ. The filing also discloses that the same account sold 548 shares on 09/02/2025 for gross proceeds of $15,386.20. These amounts are small relative to the reported 126,289,910 shares outstanding, and the filer represents no undisclosed material adverse information.

Apellis Pharmaceuticals (APLS) Form 144: proposed sale of 20,000 common shares. The notice reports an intended sale of 20,000 shares through Morgan Stanley Smith Barney on 09/10/2025 on NASDAQ with an aggregate market value of $523,436. The filing shows the seller previously acquired the shares as performance stock units and exercised options across four acquisition dates: 09/18/2018, 01/27/2021, 01/28/2022 and 09/08/2025. The filer sold 15,000 shares in the past three months across three trades on 06/16/2025, 07/16/2025 and 08/18/2025 for gross proceeds of $93,850, $97,750 and $139,000 respectively. The notice includes the standard representation that the seller is unaware of any undisclosed material adverse information about the issuer.

Apellis Pharmaceuticals insider Timothy E. Sullivan, the company's Chief Financial Officer, executed option exercises and share sales under a 10b5-1 plan on 09/08/2025. He exercised options to purchase 15,000 shares at an exercise price of $10.03, resulting in 15,000 newly acquired shares and increasing his directly held shares to 242,903. Concurrently, he sold 32,729 shares at a weighted average price of $27.86 and an additional 10,000 shares at $27.83, with sale prices ranging from $27.67 to $27.98. After these transactions, the reporting person directly owned 110,936 shares and indirectly held 60,396 shares through The Timothy E Sullivan Irrevocable Trust of 2023, which he disclaims beneficial ownership of except for his pecuniary interest. The transactions were reported on Form 4 and signed by an attorney-in-fact on 09/10/2025.